

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

SK-N-DZ

RRID:CVCL_1701

Type: Cell Line

Proper Citation

RRID:CVCL_1701

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1701

Proper Citation: RRID:CVCL_1701

Description: Cell line SK-N-DZ is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Neuroblastoma

Defining Citation: [PMID:2987426](#), [PMID:6610792](#), [PMID:12702577](#), [PMID:16822308](#), [PMID:18082704](#), [PMID:18724359](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:28350380](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian and Native North American., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-N-DZ

Synonyms: SKNDZ

Cross References: BTO:BTO_0004217, CLO:CLO_0009054, EFO:EFO_0005721, CLDB:cl4335, 4DN:4DNSRPJISWJY, AddexBio:C0005020/5011, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2149, BioGRID_ORCS_Cell_line:463, BioSample:SAMN03473093, BioSample:SAMN10988189, cancercellines:CVCL_1701,

Cell_Model_Passport:SIDM01100, CGH-DB:77-1, CGH-DB:9094-4, ChEMBL-Cells:ChEMBL3308474, ChEMBL-Targets:ChEMBL1075579, Cosmic:688086, Cosmic:897447, Cosmic:930076, Cosmic:1019931, Cosmic:1109370, Cosmic:1162004, Cosmic:1167415, Cosmic:2058115, Cosmic:2485951, Cosmic-CLP:688086, DepMap:ACH-000366, ECACC:94092305, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS373BOT, ENCODE:ENCBS439FDS, ENCODE:ENCBS478IFE, ENCODE:ENCBS514GVM, ENCODE:ENCBS520AAA, ENCODE:ENCBS521AAA, ENCODE:ENCBS580YYW, ENCODE:ENCBS707BMT, ENCODE:ENCBS715HTH, ENCODE:ENCBS773LCT, ENCODE:ENCBS893THB, GDSC:688086, GEO:GSM887594, GEO:GSM888677, GEO:GSM1366412, GEO:GSM1670451, GEO:GSM2371257, GEO:GSM2394372, IARC_TP53:27242, IGRhCellID:SKNDZ, LiGeA:CCLE_236, LINCS_LDP:LCL-1970, Lonza:1190, PharmacDB:SKNDZ_1406_2019, PRIDE:PXD010745, PRIDE:PXD030304, Progenetix:CVCL_1701, PubChem_Cell_line:CVCL_1701, Wikidata:Q54954471

ID: CVCL_1701

Record Creation Time: 20220427T221547+0000

Record Last Update: 20260913T010046+0000

Ratings and Alerts

No rating or validation information has been found for SK-N-DZ.

No alerts have been found for SK-N-DZ.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 149 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Xu A, et al. (2026) Acyltransferase ZDHHC22 promotes N-Myc transcriptional activation to drive neuroblastoma progression and chemoresistance. *Molecular cell*, 86(10), 1945.

Norouzi M, et al. (2026) DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. *Cancer letters*, 646, 218383.

Treis D, et al. (2025) Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. *Cell death & disease*, 16(1), 318.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. *Cell reports. Medicine*, 5(3), 101468.

Fusco P, et al. (2023) miR-210-3p enriched extracellular vesicles from hypoxic neuroblastoma cells stimulate migration and invasion of target cells. *Cell & bioscience*, 13(1), 89.

Karapurkar JK, et al. (2023) CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis. *Journal of experimental & clinical cancer research : CR*, 42(1), 121.

Jin L, et al. (2023) BI-D1870 Induces Mitotic Dysfunction and Apoptosis in Neuroblastoma by Regulating the PI3K-Akt-mTORC1 Signal Axis. *Cancers*, 15(7).

Wu JC, et al. (2023) ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN. *International journal of molecular sciences*, 24(2).

Martinez-Monleon A, et al. (2023) Identification of recurrent 3q13.31 chromosomal rearrangement indicates LSAMP as a tumor suppressor gene in neuroblastoma. *International journal of oncology*, 62(2).

Chang YW, et al. (2023) Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface. *Communications biology*, 6(1), 427.

Bing S, et al. (2023) AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells. *Acta pharmaceutica Sinica. B*, 13(4), 1522.

Banerjee D, et al. (2023) Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. *Cancer research communications*, 3(12), 2518.

Malone CF, et al. (2023) Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. *Cancer research*, 83(2), 285.

Brown AL, et al. (2022) TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. *Nature*, 603(7899), 131.

Holliday H, et al. (2022) miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. *Molecular therapy : the journal of the American Society of Gene Therapy*, 30(3), 1119.

Castell A, et al. (2022) MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. *Cancer research communications*, 2(3), 182.

Sorteberg AL, et al. (2022) The cyclin dependent kinase inhibitor p21Cip1/Waf1 is a therapeutic target in high-risk neuroblastoma. *Frontiers in oncology*, 12, 906194.

Mabe NW, et al. (2022) Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. *Nature cancer*, 3(8), 976.